Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.
Missing: Diamics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Diamics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Diamics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Diamics is included in 1 Expert Collection, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Diamics Frequently Asked Questions (FAQ)
Where is Diamics's headquarters?
Diamics's headquarters is located at SIX HAMILTON LANDING SUITE 200, Novato.
What is Diamics's latest funding round?
Diamics's latest funding round is Other Investors.
Who are the investors of Diamics?
Investors of Diamics include Keiretsu Forum.
Who are Diamics's competitors?
Competitors of Diamics include Dilon Technologies, Ikonisys, Decipher Biosciences, Ativa Medical, Stage I Diagnostics, Micrima, Orison, Oxford BioDynamics, Oncoscope, Real Imaging and 15 more.
Compare Diamics to Competitors
BIOCAM develops and markets systems in the field of photodynamic detection, fluorescence diagnosis and videodermoscopy. With its multifunctional products DYADERM and DermoGenius BIOCAM is leading in skin cancer detection.
Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.
MediSpectra, Inc. is a medical device company developing optical detection technology for enhanced accuracy and real-time results in the detection of cancer and other human tissue abnormalities. The technology is based on multimodal optical interrogation of tissue with light. Specifically, a combination of native fluorescence and white light backscatter spectroscopies are coupled with video imaging methods to more accurately detect tissue abnormalities. nnThe company's first product, the LUMA Cervical Imaging System, was designed and developed to improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential of becoming invasive cancer. The LUMA product is intended for use as an adjunct to colposcopy in identifying high grade disease (CIN 2/3+) in patients referred to colposcopy with an ASCUS, LSIL or HSIL+ cervical cytology test result. n
FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.
Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.
Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.